We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY
THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME
BIOADHESIVE DRUG DELIVERY COMPOSITIONS
SYNTHESIS AND CHARACTERIZATION OF SECOND GENERATION BENZOFURANONE RING SUBSTITUTED NOSCAPINE ANALOGS
CARBOCYANINES FOR G-QUADRUPLEX DNA STABILIZATION AND TELOMERASE INHIBITION
METHOD FOR CONVERTING AND PRODUCING CARBONATE MINERALS FROM CARBON DIOXIDE USING RECOMBINANT BIOCATALYST
CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA